News From The Web

‘Monumental U-turn’ by NHS in England on expensive breast cancer drug

A pioneering and life-extending drug repeatedly deemed too expensive will now be offered on the NHS in England.

It is the result of a confidential deal between the health service and the drug company Roche.

Kadcyla, the undiscounted cost of which had been £90,000 per patient, adds an average of six months of life to women with a form of terminal breast cancer.

Campaigners have praised the “monumental” U-turn, which will benefit about 1,200 women a year.

“Tough negotiation and flexibility between the NHS and Roche means both patients and taxpayers are getting a good deal,” said NHS England chief executive Simon Stevens.

Kadcyla, a combination of two drugs, is used to treat people with HER2-positive tumours that have spread to other parts of the body and cannot be surgically removed.

Read more at BBC Health.

Bookmark and Share

Post a Comment

Enter this security code

Submit Comment for Moderation